Therapeutic approaches to bladder cancer: Identifying targets and mechanisms

Richard J Cote, Ram Datar

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Transitional cell carcinoma is the second most common genitourinary malignancy in US and third most common cause of death among genitourinary tumors. Treatment options for bladder cancer include surgery, often combined with chemotherapy, radiation, and/or immunotherapy. The MVAC adjuvant chemotherapy regimen has been most widely used in locally invasive as well as metastatic disease. Only a proportion of patients at risk will respond to therapy. There is thus need to identify good responder patients for adjuvant therapy and to identify new targets to treat a greater range of patients. Based upon patient-specific aberrations in pathways or known markers, both existing and new therapies can be tailored to benefit patients based on the risk of progression and molecular alterations specific to a patient's tumor. Targeted therapy, therefore, is defined as therapy that targets mechanism and risk. Utilizing the available knowledge of the molecular biology of cell-cycle regulation, signal transduction, apoptosis, and angiogenesis in bladder cancer, we review the potential therapeutic targets for rational drug development. Finally, using bladder cancer as a model for translational research, requirements for a desired clinical trial are presented.

Original languageEnglish
JournalCritical Reviews in Oncology/Hematology
Volume46
Issue numberSUPPL.
DOIs
StatePublished - Jun 27 2003
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Therapeutics
Neoplasms
Translational Medical Research
Transitional Cell Carcinoma
Adjuvant Chemotherapy
Immunotherapy
Molecular Biology
Cause of Death
Signal Transduction
Cell Cycle
Clinical Trials
Radiation
Apoptosis
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Bladder cancer
  • Clinical trial design
  • Patient selection
  • Rational therapy
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Therapeutic approaches to bladder cancer : Identifying targets and mechanisms. / Cote, Richard J; Datar, Ram.

In: Critical Reviews in Oncology/Hematology, Vol. 46, No. SUPPL., 27.06.2003.

Research output: Contribution to journalArticle

@article{fd3619be871d481a94fedd7e579ba54f,
title = "Therapeutic approaches to bladder cancer: Identifying targets and mechanisms",
abstract = "Transitional cell carcinoma is the second most common genitourinary malignancy in US and third most common cause of death among genitourinary tumors. Treatment options for bladder cancer include surgery, often combined with chemotherapy, radiation, and/or immunotherapy. The MVAC adjuvant chemotherapy regimen has been most widely used in locally invasive as well as metastatic disease. Only a proportion of patients at risk will respond to therapy. There is thus need to identify good responder patients for adjuvant therapy and to identify new targets to treat a greater range of patients. Based upon patient-specific aberrations in pathways or known markers, both existing and new therapies can be tailored to benefit patients based on the risk of progression and molecular alterations specific to a patient's tumor. Targeted therapy, therefore, is defined as therapy that targets mechanism and risk. Utilizing the available knowledge of the molecular biology of cell-cycle regulation, signal transduction, apoptosis, and angiogenesis in bladder cancer, we review the potential therapeutic targets for rational drug development. Finally, using bladder cancer as a model for translational research, requirements for a desired clinical trial are presented.",
keywords = "Bladder cancer, Clinical trial design, Patient selection, Rational therapy, Targeted therapy",
author = "Cote, {Richard J} and Ram Datar",
year = "2003",
month = "6",
day = "27",
doi = "10.1016/S1040-8428(03)00066-0",
language = "English",
volume = "46",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL.",

}

TY - JOUR

T1 - Therapeutic approaches to bladder cancer

T2 - Identifying targets and mechanisms

AU - Cote, Richard J

AU - Datar, Ram

PY - 2003/6/27

Y1 - 2003/6/27

N2 - Transitional cell carcinoma is the second most common genitourinary malignancy in US and third most common cause of death among genitourinary tumors. Treatment options for bladder cancer include surgery, often combined with chemotherapy, radiation, and/or immunotherapy. The MVAC adjuvant chemotherapy regimen has been most widely used in locally invasive as well as metastatic disease. Only a proportion of patients at risk will respond to therapy. There is thus need to identify good responder patients for adjuvant therapy and to identify new targets to treat a greater range of patients. Based upon patient-specific aberrations in pathways or known markers, both existing and new therapies can be tailored to benefit patients based on the risk of progression and molecular alterations specific to a patient's tumor. Targeted therapy, therefore, is defined as therapy that targets mechanism and risk. Utilizing the available knowledge of the molecular biology of cell-cycle regulation, signal transduction, apoptosis, and angiogenesis in bladder cancer, we review the potential therapeutic targets for rational drug development. Finally, using bladder cancer as a model for translational research, requirements for a desired clinical trial are presented.

AB - Transitional cell carcinoma is the second most common genitourinary malignancy in US and third most common cause of death among genitourinary tumors. Treatment options for bladder cancer include surgery, often combined with chemotherapy, radiation, and/or immunotherapy. The MVAC adjuvant chemotherapy regimen has been most widely used in locally invasive as well as metastatic disease. Only a proportion of patients at risk will respond to therapy. There is thus need to identify good responder patients for adjuvant therapy and to identify new targets to treat a greater range of patients. Based upon patient-specific aberrations in pathways or known markers, both existing and new therapies can be tailored to benefit patients based on the risk of progression and molecular alterations specific to a patient's tumor. Targeted therapy, therefore, is defined as therapy that targets mechanism and risk. Utilizing the available knowledge of the molecular biology of cell-cycle regulation, signal transduction, apoptosis, and angiogenesis in bladder cancer, we review the potential therapeutic targets for rational drug development. Finally, using bladder cancer as a model for translational research, requirements for a desired clinical trial are presented.

KW - Bladder cancer

KW - Clinical trial design

KW - Patient selection

KW - Rational therapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=0037972618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037972618&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(03)00066-0

DO - 10.1016/S1040-8428(03)00066-0

M3 - Article

C2 - 12850529

AN - SCOPUS:0037972618

VL - 46

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - SUPPL.

ER -